Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 30575484

Sorafenib for Advanced and Refractory Desmoid Tumors.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2018 Dec 20
First author
Gounder MM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Cardiol. 2019 Jan;16(1):2. doi: 10.1038/s41569-018-0125-6.
    note
    Source null
    related pmid
    30478399
    relationship
    Comment in
  2. citation
    Cancer Discov. 2019 Mar;9(3):313. doi: 10.1158/2159-8290.CD-NB2019-004.
    note
    Source null
    related pmid
    30670460
    relationship
    Comment in

Authors and identifiers

  1. name
    Gounder MM
    type
    Author
  2. name
    Mahoney MR
    type
    Author
  3. name
    Van Tine BA
    type
    Author
  4. name
    Ravi V
    type
    Author
  5. name
    Attia S
    type
    Author
  6. name
    Deshpande HA
    type
    Author
  7. name
    Gupta AA
    type
    Author
  8. name
    Milhem MM
    type
    Author
  9. name
    Conry RM
    type
    Author
  10. name
    Movva S
    type
    Author
  11. name
    Pishvaian MJ
    type
    Author
  12. name
    Riedel RF
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Gounder MM
    type
    Author
  2. name
    Mahoney MR
    type
    Author
  3. name
    Van Tine BA
    type
    Author
  4. name
    Ravi V
    type
    Author
  5. name
    Attia S
    type
    Author
  6. name
    Deshpande HA
    type
    Author
  7. name
    Gupta AA
    type
    Author
  8. name
    Milhem MM
    type
    Author
  9. name
    Conry RM
    type
    Author
  10. name
    Movva S
    type
    Author
  11. name
    Pishvaian MJ
    type
    Author
  12. name
    Riedel RF
    type
    Author
bibliography ids
  1. nci-bib-e2c0c55f0c4e349b3a5795f4
book metadata
content sha256
61c8e26710f8b9495dee52d81f3db75bae888c37524625ba5f867627abad6eaa
document type
citation
dois
  1. 10.1056/NEJMoa1805052
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:30575484
immutable id
pubmed:30575484@61c8e26710f8b9495dee52d81f3db75bae888c37524625ba5f867627abad6eaa
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
25
name
The New England journal of medicine
nlm unique id
0255562
pages
2417-2428
volume
379
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Nat Rev Cardiol. 2019 Jan;16(1):2. doi: 10.1038/s41569-018-0125-6.
    note
    Source null
    related pmid
    30478399
    relationship
    Comment in
  2. citation
    Cancer Discov. 2019 Mar;9(3):313. doi: 10.1158/2159-8290.CD-NB2019-004.
    note
    Source null
    related pmid
    30670460
    relationship
    Comment in
outcomes validated
false
pmid
30575484
provenance
batch id
e808962322f3afebc564
provider
NCBI PubMed ESummary
record sha256
8537d7398880cdc51d463f36f5adc443177419a4cb2726ca5477fc663353dcfb
response sha256
3d610336ca8dae92b82cdb6b3ee6cab382eb509e0349b0c68c261b042b036561
retrieved at
2026-09-09T23:47:41.002093+00:00
publication date
display
2018 Dec 20
precision
day
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30575484/
title
Sorafenib for Advanced and Refractory Desmoid Tumors.

Preserved source evidence · Not medical advice